Engineered antibody fragments for immuno-PET imaging of endogenous CD8 + T cells in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 3, 2014, Pages 1108-1113

  Tavaré, Richard ^a   McCracken, Melissa N ^b   Zettlitz, Kirstin A ^a   Knowles, Scott M ^a   Salazar, Felix B ^a   Olafsen, Tove ^a   Witte, Owen N ^a,b   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI CD8 ANTIBODY; ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY ENGINEERING; ANTIGEN SPECIFICITY; ARTICLE; AXILLARY LYMPH NODE; BONE; CARCASS; CD8+ T LYMPHOCYTE; EX VIVO STUDY; HEART; IMMUNO POSITRON EMISSION TOMOGRAPHY; IN VIVO STUDY; INTESTINE; KIDNEY; LIVER; LUNG; MOUSE; MUSCLE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLEEN; STOMACH; THYMUS;

ALLELES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; COPPER RADIOISOTOPES; EPITOPES; FLOW CYTOMETRY; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; RATS; TISSUE DISTRIBUTION;

EID: 84892912236     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1316922111     Document Type: Article

References (32)

1. Pillay V, Gan HK, Scott AM (2011) Antibodies in oncology. New Biotechnol 28(5):518-529.
2. Rothe A, Rubbert A (2011) Recombinant proteins in rheumatology-Recent advances. New Biotechnol 28(5):502-510.
3. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23(9):1137-1146.
4. Knowles SM, Wu AM (2012) Advances in immuno-positron emission tomography: Antibodies for molecular imaging in oncology. J Clin Oncol 30(31):3884-3892.
5. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE (2004) Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol 31(8):1021-1031.
6. Pittet MJ, et al. (2007) In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci USA 104(30):12457-12461.
7. Nair-Gill ED, Shu CJ, Radu CG, Witte ON (2008) Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol Rev 221:214-228.
8. Yaghoubi SS, Campbell DO, Radu CG, Czernin J (2012) Positron emission tomography reporter genes and reporter probes: Gene and cell therapy applications. Theranostics 2(4):374-391.
9. Koya RC, et al. (2010) Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci USA 107(32):14286-14291.
10. Laing RE, Nair-Gill E, Witte ON, Radu CG (2010) Visualizing cancer and immune cell function with metabolic positron emission tomography. Curr Opin Genet Dev 20(1):100-105.
11. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354(5):496-507.
12. Mamede M, et al. (2003) Differential uptake of (18) F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification. Neoplasia 5(2):179-183.
13. Ribas A, et al. (2010) Imaging of CTLA4 blockade-induced cell replication with (18) F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51(3):340-346.
14. Aarntzen EH, et al. (2011) Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci USA 108(45):18396-18399.
15. Nair-Gill E, et al. (2010) PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest 120(6):2005-2015.
16. Olafsen T, Wu AM (2010) Antibody vectors for imaging. Semin Nucl Med 40(3):167-181.
17. Malviya G, Galli F, Sonni I, Pacilio M, Signore A (2010) Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications. Q J Nucl Med Mol Imaging 54(6):654-676.
18. MartIn-Fontecha A, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: Impact on T lymphocyte traffic and priming. J Exp Med 198(4):615-621.
19. Olafsen T, et al. (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65(13):5907-5916.
20. Natarajan A, et al. (2012) Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol 14(5):608-616.
21. Natarajan A, Habte F, Gambhir SS (2012) Development of a Novel Long-Lived ImmunoPET Tracer for Monitoring Lymphoma Therapy in a Humanized Transgenic Mouse Model. Bioconjug Chem 23(6):1221-1229.
22. Olafsen T, et al. (2010) ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 23(4):243-249.
23. Olafsen T, et al. (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50(9):1500-1508.
24. Witzig TE, et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (12):3793-3803.
25. Dijkers EC, et al. (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87(5):586-592.
26. Bumbaca D, et al. (2012) Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol 166(1):368-377.
27. Divgi CR, et al. (1991) Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 83(2):97-104.
28. Boswell CA, et al. (2012) Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 53(9):1454-1461.
29. Wu AM, et al. (2000) High-resolution microPET imaging of carcinoembryonic antigenpositive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 97(15):8495-8500.
30. Rogers BE, et al. (1996) Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: Biodistribution and metabolism. Bioconjug Chem 7(4):511-522.
31. Glockshuber R, Malia M, Pfitzinger I, Plückthun A (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29(6):1362-1367.
32. Wörn A, Plückthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305(5):989-1010.